1.29

1.57% 0.02

After Hours: 1.27 -0.02 -1.55%

Nrx Pharmaceuticals Inc (NRXP)

Overview News Price History Option Chain Financials Discussions Forecast

Nrx Pharmaceuticals Inc stock is traded at $1.29, with a volume of 39,823. It is up +1.57% in the last 24 hours and up +6.61% over the past month. NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.

Previous Close:

$1.27

Open:

$1.27

24h Volume:

39,823

Relative Volume:

0.31

Market Cap:

$15.36M

Revenue:

Net Income/Loss:

$-30.15M

P/E Ratio:

-2.2632

EPS:

-0.57

Net Cash Flow:

$-21.66M

1W Performance:

+6.61%

1M Performance:

+6.61%

6M Performance:

-67.34%

1Y Performance:

-59.91%

1-Day Range:

$1.26

$1.31

1-Week Range:

$1.1895

$1.47

52-Week Range:

$1.10

$7.333

Nrx Pharmaceuticals Inc Stock (NRXP) Company Profile

Name

Nrx Pharmaceuticals Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

484-254-6134

Address

1201 ORANGE STREET, WILMINGTON

Employee

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

NRXP's Discussions on Twitter

Compare NRXP with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NRXP Nrx Pharmaceuticals Inc	1.29	15.36M	0	-30.15M	-21.66M	-0.57
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Nrx Pharmaceuticals Inc Stock (NRXP) Latest News

Nov 27, 2024

NRx Pharmaceuticals (NRXP) Upgraded to Buy: Here's Why - Yahoo Finance

Nov 27, 2024

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter - GuruFocus.com

Nov 27, 2024

Nov 26, 2024

NRx Pharmaceuticals (NASDAQ: NRXP) Announces Participation in the NobleCon20Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference December 3-4, 2024 - PR Newswire

Nov 26, 2024

Nov 25, 2024

NRx Pharmaceuticals reiterates shares target with Buy rating on Q3 report - Investing.com Nigeria

Nov 25, 2024

NRx Pharma Achieves 94.5% Rating Accuracy Breakthrough in Depression Trial Method | NRXP Stock News - StockTitan

Nov 25, 2024

Nov 20, 2024

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Receipt of Po - GuruFocus.com

Nov 20, 2024

Earnings call: NRx Pharmaceuticals projects profitability by 2025 - Investing.com Canada

Nov 20, 2024

NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Michael Abrams as Chief Financial Officer - The Malaysian Reserve

Nov 20, 2024

Nov 19, 2024

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 19, 2024

Nov 18, 2024

NRx Pharmaceuticals Reports Progress in Drug Development - TipRanks

Nov 18, 2024

NRx Pharmaceuticals names Michael Abrams as new CFO - Investing.com

Nov 18, 2024

NRx Pharmaceuticals, Inc. Announces Chief Financial Officer Changes - Marketscreener.com

Nov 18, 2024